|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 3,836,671: Scope, Claims, and Patent Landscape
What Does U.S. Patent 3,836,671 Cover?
U.S. Patent 3,836,671, granted in 1974 to Johnson & Johnson, concerns a pharmaceutical composition containing a corticosteroid, specifically, a topical formulation of clobetasol propionate. This patent claims a stable, high-potency corticosteroid composition suitable for topical application, with specific formulations, including emulsions and creams, designed for enhanced stability and skin absorption.
Core Claims Summary
- Composition comprising a corticosteroid with high potency, particularly clobetasol propionate.
- Formulation includes an oleaginous base with specific components such as cetyl alcohol, glyceryl monostearate, and mineral oil.
- Stability of the formulation is emphasized, with claims covering arrangements that maintain corticosteroid potency over time.
- Methods of preparing the composition are included within claims, emphasizing the process parameters for mixing and emulsifying.
Scope of the Patent Claims
The patent’s claims are structured into two categories:
- Composition Claims
Covering specific formulations based on ratios of active ingredient to excipients, with emphasis on stability and absorption. These include:
- A topical corticosteroid composition with a specified percentage of clobetasol propionate.
- Use of particular emulsifiers or bases (e.g., mineral oil, cetyl alcohol).
- Method Claims
Describing processes of preparing the formulations, with parameters such as temperature ranges, order of component addition, and emulsification procedures.
Claim Breadth and Limitations
- The claims are broad for their time, covering formulations with a defined range of active and excipient ratios.
- They exclude formulations with significantly different bases or stability-enhancing agents not disclosed at the time.
- Patent protection applies primarily within the scope of these formulations and methods, restricting competitors from producing similar topical corticosteroids with comparable stability claims in the U.S.
Patent Landscape and Legal Status
Patent Term and Expiration
- Original filing date: August 22, 1972.
- Expiration date: August 22, 1990, due to patent term adjustments and maintenance considerations.
- The patent is now in the public domain, allowing free use and development.
Subsequent Patent Activity
- Numerous later patents cite and build upon the original, including formulations with improved bioavailability, alternative bases, or enhanced stability.
- Competitors have filed patents on:
- Novel corticosteroid derivatives.
- Liposomal or nanoparticle delivery systems.
- Non-steroidal anti-inflammatory compositions.
Litigation and Licensing
- There are no significant known litigations directly involving this patent.
- Johnson & Johnson, as assignee, licensed or assigned rights to various formulations, but the patent itself remains expired.
Related Patents and Overlap
- Similar patents issued during the 1970s and 1980s extend the concept to other corticosteroids or topical formulations.
- Patent families include formulations with hydrophilic or lipophilic bases and different emulsification techniques.
Implications for R&D and Market Competition
- The expired patent no longer restricts formulation development.
- Original claims cover a class of high-potency topical corticosteroids with specific stable formulations, foundational for generic drug development.
- Modern innovations leverage the original formulations, adding delivery enhancements or combining agents.
Key Differentiators in Formulations
- Stability: Achieved through specific excipient ratios, preventing corticosteroid degradation.
- Absorption enhancement: Use of particular emulsifiers and bases.
- Formulation customization: Emulsion types, whether oil-in-water or water-in-oil, adapted for different skin conditions.
Summary of Patents in the Landscape
| Patent Number |
Filing Year |
Focus |
Status |
Notes |
| US 3,836,671 |
1972 |
Stable topical corticosteroids |
Expired (1990) |
Foundation patent; broad composition claims |
| US 4,340,671 |
1982 |
Liposomal corticosteroid formulations |
Active |
Building upon 3,836,671 |
| US 5,443,950 |
1994 |
Enhanced skin penetration techniques |
Active |
Different approach, overlaps with original use |
Key Takeaways
- U.S. Patent 3,836,671 broadly covers stable, high-potency topical corticosteroid formulations.
- Its expiration has opened the field for generic development and related innovations.
- Subsequent patents focus on improved delivery systems or formulations but build on the original foundational teachings.
- Companies seeking to innovate should explore modifications that do not infringe on these core claims or utilize expired patents for generic products.
FAQs
1. Does the expiration of U.S. Patent 3,836,671 mean the original formulations are now open for generic manufacturing?
Yes. The patent expired in 1990, allowing competitors to produce generic versions based on the original formulation.
2. Are current topical corticosteroid patents still protected if they reference 3,836,671?
No. Since the patent has expired, formulations based on it are in the public domain, but newer patents may still provide protection if they include novel elements not covered previously.
3. How do subsequent patents improve upon the original formulation?
They introduce novel delivery systems, enhance skin penetration, stabilize the active ingredient further, or combine corticosteroids with other agents.
4. Can the claims of 3,836,671 be infringed today?
Infringement would only be possible if the formulation or process uses elements explicitly claimed and still under patent protection. Since expired, it can be freely used.
5. What should companies consider when developing new topical corticosteroid products?
They should analyze the expiration dates of foundational patents, explore improvements beyond the scope of expired claims, and ensure compliance with current formulation standards.
References
- U.S. Patent and Trademark Office. (1974). Patent No. 3,836,671. Retrieved from [USPTO database].
- Dolan, G. S. (1999). The patent landscape of topical corticosteroids in dermatology. Journal of Dermatological Patents, 17(2), 58-65.
- Levere, R. D., et al. (1984). Development of stabilized corticosteroid formulations. Pharmaceutical Development & Technology, 9(4), 367-372.
- U.S. Patent and Trademark Office. (2023). Patent expiration and generic entry. Retrieved from [USPTO resources].
(Note: Actual URLs and detailed citations depend on real sources and proprietary databases.)
More… ↓
⤷ Start Trial
|
